Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 14/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780198 | 1.00 | TRPM5 (1.00) | TRPM5MAPTKDM4EALDH1A1GAA | |
| SCHEMBL1223555 | 1.00 | TRPM5 (1.00) | TRPM5MAPTKDM4EALDH1A1GAA | |
| SCHEMBL1224865 | 1.00 | TRPM5 (1.00) | TRPM5MAPTKDM4EALDH1A1GAA | |
| SCHEMBL1223557 | 1.00 | TRPM5 (1.00) | TRPM5MAPTKDM4EALDH1A1GAA | |
| SCHEMBL1223738 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL1223939 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL1223942 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL1223739 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL1224066 | 0.90 | TRPM5 (1.00) | TRPM5KDM4EALDH1A1GAALMNA | |
| SCHEMBL1224070 | 0.90 | TRPM5 (1.00) | TRPM5KDM4EALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | claimed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | claimed |
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | TRPM5, TRPV5, TRPM8 | TRPM5 1/4885MAPT 3601/4885KDM4E 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.